STOCK TITAN
  1. Home
  2. News
  3. TERN

Terns Pharmaceuticals, Inc. - TERN STOCK NEWS

Welcome to our dedicated page for Terns Pharmaceuticals news (Ticker: TERN), a resource for investors and traders seeking the latest updates and insights on Terns Pharmaceuticals stock.

Terns Pharmaceuticals, Inc. (Nasdaq: TERN) is a clinical-stage biopharmaceutical company with a mission to innovate and develop small-molecule, molecularly-targeted, oral therapies for the treatment of serious diseases, including liver diseases and cancers. Based in San Mateo, California and Shanghai, Terns leverages its expertise in disease biology and medicinal chemistry to advance its growing pipeline of drugs aimed at addressing significant unmet medical needs globally.

The company is renowned for its cost-efficient drug discovery model and robust clinical development capabilities, especially within China. Terns Pharmaceuticals is focused on developing a portfolio of small-molecule candidates tailored for non-alcoholic steatohepatitis (NASH), oncology, and obesity.

One of the company's flagship programs is the TERN-501, an investigational orally administered thyroid hormone receptor-β (THR-β) agonist aimed at treating NASH. The Phase 2a DUET clinical trial revealed promising results, showing significant impacts on liver fat content and fibro-inflammation markers within a short period. This positions TERN-501 as a potential leading therapy for NASH.

Additionally, Terns is developing TERN-701, an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML), and TERN-601, a small-molecule GLP-1 receptor agonist for obesity. Both candidates have shown encouraging preclinical and early clinical data, promising significant advancements in their respective fields.

Financially, as of the latest quarter, Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, supporting the planned operating expenses into 2026. Recent clinical trials and corporate updates highlight the company's ongoing dedication to addressing global health challenges through innovative drug development.

For more information, please visit their website at www.ternspharma.com.

News

Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer

Rhea-AI Summary
Terns Pharmaceuticals, Inc. appoints Melita Sun Jung as chief business officer, bringing over 20 years of experience in the life sciences industry. With a focus on driving valuable partnerships and strategic decisions, her expertise will be instrumental in propelling Terns' oncology and metabolic pipeline programs to mid- and late-stage development. Ms. Jung's track record includes successful collaborations and licensing deals, making her a valuable addition to Terns' leadership team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.57%
Tags
management
-
News

Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Rhea-AI Summary
Terns Pharmaceuticals, Inc. reports positive financial results and pipeline updates for 2023. Interim data from Phase 1 trials of TERN-701 and TERN-601 expected in the second half of 2024. Cash position of $263 million to support operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.3%
Tags
earnings
-
News

Terns Pharmaceuticals Announces Orphan Drug Designation Granted to TERN-701 for the Treatment of Chronic Myeloid Leukemia

Rhea-AI Summary
Terns Pharmaceuticals, Inc. receives Orphan Drug Designation from the FDA for TERN-701, a potential treatment for chronic myeloid leukemia. The drug is an allosteric BCR-ABL tyrosine kinase inhibitor in Phase 1 clinical development, with promising interim data expected in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.04%
Tags
clinical trial
News

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. granted an equity inducement award to a new employee under the Inducement Plan, with options to purchase 45,000 shares of Terns common stock at an exercise price of $7.31 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.97%
Tags
none
-
News

Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences

Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced participation in upcoming investor conferences in March to discuss their small-molecule product candidates for serious diseases like oncology and obesity. The events include TD Cowen 44th Annual Health Care Conference and Inaugural BMO Obesity Summit, with live webcasts available on the company's investor relations page.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.26%
Tags
conferences
-
News

Terns Pharmaceuticals Reports Inducement Grants to New Chief Executive Officer Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced the granting of equity inducement awards to its new CEO, Amy Burroughs, under the 2022 Employment Inducement Award Plan. The awards include an option to purchase 1,250,000 shares of Terns common stock and a restricted stock unit award representing the right to receive 150,000 shares of Terns common stock. The option vests over four years, and the restricted stock unit award vests based on the achievement of milestones stock prices with respect to Terns common stock.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.81%
Tags
none
News

Terns Pharmaceuticals Appoints Amy Burroughs as Chief Executive Officer

Rhea-AI Summary
Terns Pharmaceuticals, Inc. announced the appointment of Amy Burroughs as chief executive officer and her addition to the board of directors. Burroughs brings over 25 years of leadership experience, having led therapeutics and commercial strategies at various companies. Her appointment is aimed at advancing Terns' programs to later stage development and partnership, particularly in oncology and metabolic diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.13%
Tags
management
-
News

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. granted an equity inducement award to a new employee under the terms of the 2022 Employment Inducement Award Plan, as amended. The award consists of options to purchase 19,000 shares of Terns common stock with a 10-year term and an exercise price per share equal to $5.26. The options vest over four years, subject to the employee’s continued service through the applicable vesting dates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
none
-
News

Terns Pharmaceuticals to Highlight 2024 Priorities and Clinical Milestones at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) plans to advance its diverse pipeline of programs in oncology and metabolic diseases, with key proof-of-concept readouts for TERN-701 (CML) and TERN-601 (obesity) anticipated in 2H24. The company is prioritizing capital allocation to its oncology and obesity programs, with cash and cash equivalents of $267M expected to provide runway into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
none
News

Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)

Rhea-AI Summary
Terns Pharmaceuticals, Inc. (TERN) announced the granting of an equity inducement award to a new employee under the 2022 Employment Inducement Award Plan. The award consists of options to purchase 19,000 shares of Terns common stock at an exercise price of $6.49 per share, with a 10-year term and vesting over four years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.52%
Tags
none

FAQ

What is the current stock price of Terns Pharmaceuticals (TERN)?

The current stock price of Terns Pharmaceuticals (TERN) is $5.71 as of November 21, 2024.

What is the market cap of Terns Pharmaceuticals (TERN)?

The market cap of Terns Pharmaceuticals (TERN) is approximately 483.3M.

What does Terns Pharmaceuticals, Inc. specialize in?

Terns Pharmaceuticals specializes in discovering and developing molecularly-targeted, oral, small-molecule drugs for liver diseases and cancers.

Where is Terns Pharmaceuticals located?

Terns Pharmaceuticals is based in San Mateo, California and Shanghai, China.

What is TERN-501 and what disease does it target?

TERN-501 is an investigational orally administered thyroid hormone receptor-β (THR-β) agonist developed for the treatment of non-alcoholic steatohepatitis (NASH).

What are the main therapeutic areas Terns Pharmaceuticals focuses on?

Terns Pharmaceuticals focuses on oncology, obesity, and non-alcoholic steatohepatitis (NASH).

What is the significance of TERN-701?

TERN-701 is an allosteric BCR-ABL inhibitor for chronic myeloid leukemia (CML) and represents a novel class of therapy with superior efficacy and safety profiles.

How is Terns Pharmaceuticals funded for its operations?

Terns Pharmaceuticals reported cash, cash equivalents, and marketable securities amounting to $266.6 million, which they expect to support planned operating expenses into 2026.

What recent achievement has Terns Pharmaceuticals made in clinical trials?

Terns Pharmaceuticals recently announced positive top-line data from its Phase 2a DUET clinical trial of TERN-501 for NASH, showing significant improvements in liver fat content and fibro-inflammation markers.

What is TERN-601 being developed for?

TERN-601 is a small-molecule GLP-1 receptor agonist being developed for the treatment of obesity.

What is the main objective of Terns Pharmaceuticals?

The main objective of Terns Pharmaceuticals is to bring novel, effective small-molecule therapies to market that address significant unmet medical needs globally.

Where can I find more information about Terns Pharmaceuticals' research and development activities?

You can find more information about Terns Pharmaceuticals' research and development activities on their official website at www.ternspharma.com.

Stock TERN logo
Terns Pharmaceuticals, Inc.

Nasdaq:TERN

TERN Rankings

#3144 Ranked by Market Cap
N/A Ranked by Dividends

TERN Stock Data

483.30M
77.26M
0.14%
97.69%
5.38%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FOSTER CITY